Juno Therapeutics Inc. buy tamam
Start price
25.08.15
/
50%
€32.52
Target price
18.09.15
€51.09
Performance (%)
16.09%
End price
18.09.15
€37.75
Summary
This prediction ended on 18.09.15 with a price of €37.75. The prediction had a final performance of 16.09%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Juno Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | 1,93 % | -2,11 % | 11,14 % | 59,64 % |
| iShares Nasdaq 100 | -0,18 % | -5,90 % | -0,15 % | 82,45 % |
| iShares Nikkei 225® | 7,08 % | 6,46 % | 28,83 % | 59,33 % |
| iShares S&P 500 | -0,20 % | -3,67 % | -0,10 % | 55,65 % |
Comments by tamam for this prediction
In the thread Juno Therapeutics Inc. diskutieren
collaboration agreement with oncology-giant Celgene, and an impressive pipeline
Juno Therapeutics (NASDAQ:JUNO): For my last name, I'm piggy-backing off an idea by one of the best biotech investors and smartest guys I know, Brad Loncar. Brad runs the Loncar Cancer Immunotherapy Index (LCINDX), a basket of biotech stocks that seeks to track the performance of the immuno-oncology space. Key names in the index include Celgene, Newlink Genetics, Amgen, Pfizer, Novartis, Kite, Ziopharma, and Juno Therapeutics. Brad likes Juno because they recently signed a major collaboration agreement with oncology-giant Celgene. I agree with Brad; this is a fantastic validator of the platform and should be highly lucrative for both companies. But Juno also has one heck of an impressive pipeline. If you want to play CAR or CAR T, and you should, then Juno is a must-own. The pipeline is packed with catalysts and they have over $1.3 billion in cash on hand.
(Vom Mitglied beendet)